Peripheral arterial disease cell therapy - MultiGene Vascular Systems

Drug Profile

Peripheral arterial disease cell therapy - MultiGene Vascular Systems

Latest Information Update: 22 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MultiGene Vascular Systems
  • Class Cell therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Peripheral arterial disorders; Peripheral ischaemia

Most Recent Events

  • 22 Sep 2015 Peripheral disease cell therapy completed phase-I/II development for Periperal arterial disorders in USA and Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top